{
  "name" : "twin.sci-hub.se_6186_5d5bc88f23bcde2e85d6f41544113c4f_v2016.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Nanomaterials as a game changer in the management and treatment of diabetic foot ulcers",
    "authors" : [ "M. V. Vellayappan", "S. K. Jaganathan" ],
    "emails" : [ "saravana@tdt.edu.vn." ],
    "sections" : [ {
      "heading" : null,
      "text" : "This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.\nAccepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.\nYou can find more information about Accepted Manuscripts in the author guidelines.\nPlease note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the ethical guidelines, outlined in our author and reviewer resource centre, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.\nAccepted Manuscript\nrsc.li/rsc-advances\nRSC Advances\nView Article Online View Journal\nThis article can be cited before page numbers have been issued, to do this please use: M. V, S. K. Jaganathan and M. A, RSC Adv., 2016, DOI: 10.1039/C6RA24590K."
    }, {
      "heading" : "RSC Advances",
      "text" : "Review\nThis journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 1\nPlease do not adjust margins\na. Faculty of Biosciences and Medical Engineering, Universiti Teknologi Malaysia,\nJohor Bahru 81310, Malaysia. b. Department for Management of Science and Technology Development, Ton Duc\nThang University, Ho Chi Minh City, Vietnam c. Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam d. IJN-UTM Cardiovascular Engineering Centre, Universiti Teknologi Malaysia, Johor\nBahru 81310, Malaysia. e. Department of Chemistry, Bharath University, Chennai, Tamil Nadu 600 073, India\n† Corresponding author: Dr. Saravana Kumar Jaganathan, Department for Management of Science and Technology Development; Ton Duc Thang University; 19 Nguyen Huu Tho Street, Tan Phong Ward, District 7, Ho Chi Minh City, Vietnam IJN-UTM Cardiovascular Engineering Centre, Faculty of Biosciences and Medical. Engineering, Universiti Teknologi Malaysia, Johor Bahru 81310, Malaysia. Email: saravana@tdt.edu.vn.\nReceived 02nd Oct 2016, Accepted 00th January 20xx\nDOI: 10.1039/x0xx00000x\nwww.rsc.org/\nNanomaterials as a game changer in the management and treatment of diabetic foot ulcers\nM. V. Vellayappan a , S. K. Jaganathan b-d† , and A. Manikandan e\nNanoengineered biomaterials have tremendously improved the range of tools utilized for control as well as acceleration of diabetic foot ulcer (DFU) healing over the last few decades. Despite nanoparticles and electrospun nanofibers have been used extensively for the treatment of DFU, there is no review available till now which addresses the utilization of latest nanodelivery techniques along with modern electrospun nanofibers treatment for DFU treatment. This review thoroughly summarizes the latest mindboggling findings of the potential nanomaterials like polymeric and metallic nanoparticles and electrospun nanofibers for DFU treatment. In addition, a succint insight on the potential of the aforementioned nanomaterials which can be exploited as therapeutic delivery agents for improving the regeneration of damaged dermal and epidermal tissues of DFU were underscored. Ultimately, current challenges and future prospects of nanoparticles and electrospun nanofibers for DFU treatment were highlighted."
    }, {
      "heading" : "1. Introduction",
      "text" : "Diabetes mellitus (DM) is a progressive and chronic endocrine problem that occurs most commonly in hyperglycemia (excess of blood glucose level) patients. Diabetes is contemplated to be one of the dreadful and major health problems in the world, with an alarming increase. The diabetes occurrence amongst different age groups across the globe was 2.8% in 2000 (171 million) and it is predicted to increase (4.4%) by 2030 (366 million). At present it is found that 200 million patients across the globe are affected by diabetes and this count is estimated to rocket by 333 million by 2025. The highest increase in the diabetic patients is estimated in developing countries (4.2% to 5.6%). 1, 2 In general patients with diabetes either completely lack of insulin level (type 1 DM) or have very little insulin or cannot use the produced insulin efficiently (type 2 DM). In case of type 1 DM, the body’s immune system kills the cells that release insulin thereby leading to complete elimination of insulin production in the body. However, in type 2 DM, the patient’s body becomes incapable of utilizing the insulin properly. This\ncondition is known as insulin resistance. When the type 2DM gets worse, the pancreas will produce lesser insulin and this is known as insulin deficiency. Epidemiological studies have dictated that the worldwide prevalence of type 1 DM has been incrementing by 2–5% where almost 1 in 300 at the age of 18 years in the United States. 3 The global incidence of type 2DM has shown tremendous growth over the past few decades. 4, 5 By the year 2025, it is predicted that there will be 40 million diabetic patients in China and India alone. 6 According to the statistics of the International Diabetes Federation, two individuals will develop diabetes and another two will die of diabetes-related complications every 10 seconds across the globe. 7 Hence, diabetes has become a critical public health problem that results in a tremendous socioeconomic burden.\nNearly 25% of diabetic patients suffer from a higher reported life time risk of developing foot complications 8 , and the diabetic foot ulcer (DFU) is the most common complication with an estimation of 25 to 80%. 9 Most of the foot ulceration finally turns into diabetic gangrene if left untreated, result in approximately 80% of lower limb amputations. 10-13 More than 50% of diabetic wounds can exponentially increase the risk of below-knee amputation 14-16 , which appreciably increases mortality apart from resulting in debilitating complications. 17-20 Mostly, DFU involves the toes. 21 If appropriate therapy is not conferred, the amputation of the affected bone becomes unavoidable. 22\nDifferent treatment approaches have been adopted\nto treat DFU such as the use of topical wound-care therapies. 23 Even though various topical and systemic compounds were used either alone or with combination of different materials to prevent\nPage 1 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "REVIEW RSC Advances",
      "text" : "2 | RSC Advances., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\ninfections, many have been eliminated because of developing bacterial resistance to antiseptics and antibiotics. 24, 25 These agents have resulted in the emergence and subsequent rapid overgrowth of resistant bacterial strains, drug side effects, and organ-specific toxicity. 24-26 Diabetic wound infections due to drug-resistant organisms are now becoming quiet common and they have significantly increased resistance to common antibiotics. 27\nNanotechnology may play a crucial role for diagnosing, repairing, controlling and even building our human biological systems at the cellular level. This feat is only possible if we can manipulate atoms and molecules at the nanometer scale. The nanomaterials functions at the range almost identical to the building blocks of the human cells. Thus, the nanotechnology confers fascinating pathways to revolutionize today’s medicine. Nanotechnology based treatment to ameliorate diabetes is one of the most focused research areas, at present. The nanoparticles can be used in different forms like endogenous bearing molecules, conjugated nanoparticles and pure form to treat DFUs. Likewise, the electrospun nanofibers may also be exploited for treatment of DFUs. Hence, in this article the potential application of above mentioned two classes of nanomaterials which are nanoparticles and electrospun nanofibers in the treatment and management of DFU is presented. In order to understand the pathophysiology of DFUs, the difference between the normal wound healing and DFUs is given in the following section."
    }, {
      "heading" : "2. Comparison between normal and DFU",
      "text" : "wound\nWound healing is an intricate process involving different\ntypes of cells. 28, 29 The five wound healing stages does not occur in a particular period but may overlap. 30-32 Transition between the stages primarily depends on the maturation as well as differentiation of different skin cells. The Fig. 1 shows the different phases involved in wound healing which are impaired for diabetic patients.\nIn general, re-epithelialization commences following after few hours of injury. Owing to the presence of bioactive growth factors like the keratinocytes and activated fibroblasts will arrive at the wound site where they will multiply and form a ECM accelerating the wound closure. 28, 30 For inducing angiogenesis, the proteases activity is also necessary. 33, 34 In the ultimate stage of wound healing, the degradation of the granulation tissue and dermis regeneration occurs. 35 The acute wounds generally recovers linearly via the different wound healing phases, however the DFU healing is not the same where it may stop in any one or more of aforementioned wound healing stages. 31 Similar to acute wounds, in order to\naccelerate DFU healing processes. This is necessary for the long-term healing from contamination/infection, to avert wound dissection for providing conducive environment for wound healing. 36\nDifferent treatment approaches have been adopted such\nas the use of topical wound-care treatment. 23 Even though various topical and systemic compounds were used either alone or with combination of different materials to prevent infections, many have been eliminated because of resistance. These agents have resulted in the quick overgrowth of resistant bacterial strains, drug side effects, and organ-specific toxicity. 24-26 DFU infections due to drug-resistant microbes are increasing day by day and they have significantly increased resistance to common antibiotics. This have resulted in increased costs, morbidity, and mortality rate due to diabetic wounds. 27 There are more research has been carried out on wound care with a special interest for new therapeutic treatment modalities and the development of technologies for acute and chronic wound management. 37-39 Hence, in the following section, the potential application of nanoparticles for treatment of DFU is discussed."
    }, {
      "heading" : "3. Nanoparticle for encapsulation of endogenous",
      "text" : "molecules for DFU\nAs discussed earlier, the wound healing pattern can be modulated using proteins like cytokines and growth factors. 40 Since the soluble proteins exert a control on wound repair, they have gained increasing interest for DFUs. Studies indicate that aforementioned exogenous recombinant growth factors were tested for the past one decade to accelerate the DFU healing. 41 Despite there are several pilot studies showing good results, the overall result has been not promising enough. To date, the US FDA have approved only PDGF-BB for diabetic foot ulcers treatment. 42 The major setback in the utilization of topical use of growth factor is its short half-life period. 33 Thus, growth factor utilization in pristine form is barricaded by its breakdown instigated by the proteolytic enzymes at the wound site. 43 Multitude of efforts has been taken to confer resistance to them from the enzymatic degradation. At present, the advent of nanoscale systems for drug delivery have opened up wide range of opportunities to improve the efficiency of the endogenous molecules to deliver for a prolonged period in a controlled manner. 44 There are basically six potential endogenous molecules for diabetic foot ulcer treatment which will be discussed as follows.\nPage 2 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 3\nPlease do not adjust margins\nPlease do not adjust margins\nThrombin has a notable role in the fibrin clot formation as\nwell as platelet activation where it triggers the chemotaxis and aggreagation of neutrophils, lymphocytes, and monocytes cell. Moreover, it also stimulates the growth of fibroblasts, epithelial cells and endothelial cells. 45, 46 Hence, it has a pivotal role in triggering the early events involved in the cellular events of tissue repair. The thrombin receptor activating peptides may provide a useful mimic of the natural effect of thrombin interaction with various cells. 47 Recently, nanotechnology has provided a potential method to improve its bioavailability via conjugation with iron oxide nanoparticles (γ-Fe2-O3 conjugation). 48, 49 In vivo test results depicts that the wound response to the treatment of γ-Fe2-O3 was remarkable. The wound’s tensile strength was analyzed indicates appreciable acceleration of healing process in the γ-Fe2-O3 treated wound against untreated wounds.\nNitric oxide is a small radical which is made of amino acid\nL-arginine. The NO aids wound healing in unique ways in animal wound healing models. 50 NO possess good antimicrobial properties. 51 The utilization of NO for wound healing therapy was been unresolved until now. Different trials using novel NO therapies, in the form of nitric oxide donors, have be found to have limited ability in treatment of cutaneous infection. 52 Nanomaterials recently made this challenging task possible by providing the ability to store and deliver small gaseous short-lived NO for exhibiting their antibacterial activity. The NO remains trapped within a hydrogel where it is stable until it gets exposed to the moisture environment. 53 The hydrogel provides an ideal matrix to easily store and use NO when it is required. This sustained release provides an advantage to the nanoparticles compared to other vehicles, like injections, that release a higher concentration of the drug rapidly. Easy storage, application and the provision to change the release rate and concentration with minimal risk of toxicity make this\nFig.1 Phases of wound healing which are impaired for diabetic patients\nPage 3 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "REVIEW RSC Advances",
      "text" : "4 | RSC Advances., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\npowder formulation potential candidate for cutaneous delivery. There are other similar researches that demonstrate the effectiveness of NO-releasing nanodelivery systems in the treatment of DFU. 54, 55 Similarly, NO-releasing silica nanomolecules was possess good bactericidal activity against Pseudomonas aeruginosa 56 and Acinetobacter baumannii 57 which have high level of resistance against common antibiotics. 58 Moreover, NO was also found to possess antimicrobial activity apart from directly involving in the wound healing process. Hence, the utilization of NO-releasing nanoparticles may improve DFU healing by promoting angiogenesis and tissue remodeling as well as by killing bacteria.\nThe growth factors gained a significant attention for\nwound healing in recent days. They possess the ability to speed up the wound healing via cells migration to the wound site (TGF-β), stimulates proliferation of epithelial cells and fibroblasts (FGF and PDGF), initiates new blood vessels development (FGF and VEGF), and ulitmately involved in scar formation. 33 In vivo efficiency of growth factors performance can be improved by preventing its degradation from proteolytic enzymes. This can be achieved by prolonging the duration which growth factors at the delivery site. 59, 60 Poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) are biodegradable polymers which have good biocompatibility. Longterm in vivo circulation can be achieved using surface that is generally modified with polyethylene glycol (PEG). 61 When biodegradable nanocarriers are used, the release of the active constituents like growth factor can be controlled by polymer degradation rate. 62 Recently, hyaluronan-based (HYAFF11) porous nanoparticles were loaded with PDGF for DFU treatment. 63 The PDGF has been used from last two decades to accelerate chronic wound healing. 64 HYAFF11 is a biopolymer that can be used for biomedical applications like in vitro skin reconstruction. 65 HYAFF particles possess potential to absorb growth factors and release them periodically as well as in a controlled manner. Hence, this technique of specific controlled and localized PDGF release possesses the potential to accelerate DFU wound healing.\nOpioids are recently explored to promote keratinocytes\nmigration. 66 This area of research has gained great interest since it accelerates the possible wound healing via topical application of opiods. The common treatment modalities for DFU fails in terms of providing necessary pain control in patients because of lack of\nsufficient drug concentrations at the target site. 67 As painful wound dressing changes needs prolonged duration, it must be comprised of releasing opiods for an extended duration. Bigliardi et al., demonstrated the nanoparticulate carriers to increase opiods skin penetration and delay the release of loaded drug. 67 The study carried out on the human keratinocytes depicted that opioids trigger cell migration and leads to the closure of the experimental wounds. This increased cell migration is concentration dependent. It can be stopped by the opioid receptor antagonist naloxone, dictating a specific opioid-receptor interaction. Similarly, in another study, Kuchler demonstrated that the morphine loaded in solid lipid nanoparticles had quickened the wound healing process by accelerating the reepethilialization in a human 3D wound healing modal. 68 It was observed that the keratinocytes almost covered the wound in just four days which was in contrary to the case applying unloaded particles. To conclude, decreased cytotoxicity, irritation, extended period of the morphine release makes this solid lipid nanoparticle a fascinating option for the treatment and management of DFUs.\nMatrixmetalloproteinases (MMPs) breaks most of the\nmacromolecules during maturation phase of the wound. 69 This phase requires perfect balance between collagen production, breakdown, and remodelling. Activity of MMP is controlled by specific tissue inhibitors. Good coordination between the MMP and TI is obligatory to achieve optimum wound maturation. Hence, recent researches are focused on the improving the remodeling phase. In a recent work, Norling et al., utilized aspirin-triggered D1 and lipoxin A4 analogs and developed a carrier. 70, 71 Its ability to accelerate the wound healing was examined in a mice model. Polymorphonuclear cell influx displayed good result in reducing the wound size that ultimately resulted in accelerated healing. Hence, potentials of nanoparticles to bear endogenous molecules for DFU were discussed in this section. In the upcoming section, the nanoparticles ability to deliver antiobiotic for DFU treatment will be discussed."
    }, {
      "heading" : "3.1. Nanodelivery utilizing antibiotics for DFU",
      "text" : "treatment\nDFU infection is one of the major challenging issues\nexacerbating the tissue damage. 72 Pharmacological treatment faces\nPage 4 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 5\nPlease do not adjust margins\nPlease do not adjust margins\nnumerous challenges owing to the reason of increase in antibiotic resistant strains. For instance, resistance to penicillin by Staphylococcus aureus leads to the failure of treatment against staphylococcal local infections. 73 The antibiotic therapy through nanoparticles provides promising solutions for DFU treatment. Exceptional physiochemical traits of nanoparticulate drug delivery systems allow optimum management of size, surface charge, and nature for the delivery of antibiotics in vivo. 74\nMost advanced as well effective treatment for\nstaphylococcal infection is vancomycin. The vancomycin-modified nanoparticles have been synthesized for increasing the pharmacokinetics of the antibiotic molecule. Hachicha et al., demonstrated the utilization of vancomycin-conjugated nanoparticles for intraocular continuous release injection for endophthalmitis prophylaxis. 75 It was observed that the drug concentration was maintained to be more than the minimal inhibitory limit for 24 hours. Likewise, Chakraborty et al. depicted the use of carboxymethyl chitosan-based nanoparticles loaded with vancomycin as well as proved its effectiveness against drugresistant staphylococcal strains. 76 Similarly, in a recent study by Chakraborty et al., a folic acid tagged nanosized chitosan vehicle was loaded with vancomycin to study its efficacy against the drug resistant S. aureus. 77 The study results revealed that the tolerance level of the strains to vancomycin and nanoconjugated vancomycin was almost similar. However, in case of the drug resistant S. aureus strains the tolerance level reduced when nanoconjugated vancomycin was utilized. In addition, it was also observed that the nanoconjugated vancomycin reduced the minimum inhibitory concentration (MIC) and minimum bactericidal concentration values of vancomycin resistant S. aureus strains. Nevertheless, without folic acid tagging, the chitosan nanodelivery was found to be inefficient against drug resistant strains. This is because the folic acid is a significant nutrient required for nucleotide synthesis for the bacteria, it aids to transport the chitosan nanoparticle loaded with vacomycin drug via endocytosis across the plasma membrane into the cytoplasm. 78, 79 Hence, this promising solution has tremendous potential in circumventing the problem associated with the vancomycin resistant S. aureus.\nThe ability of nanobiotechnology to improve the\ntherapeutic potential of antibiotic molecules can be further\nelucidated by the case of N-methylthiolated β-lactams.: This has been recognized to possess efficient antibacterial activity against Staphylococcus bacteria, including MRSA. This β-lactams compound exhibits growth inhibitory effects on bacteria via a mode of action that is unique compared to other β-lactam antibiotics and it possesses different structure-activity patterns. However, its limitation is poor water solubility property. 80 Hence, Turos et al., developed a novel method to obtain an emulsion of polyacrylate nanoparticles where the drug monomer was encapsulated in a polymeric matrix. In vitro studies dictate the nanoparticles are nontoxic to human skin cells. 81"
    }, {
      "heading" : "3.2 Nanodelivery routes for Gene therapy in DFU",
      "text" : "The polymeric gene delivery system possesses some\nbenefits for the plasmid DNA delivery such as it protects the plasmid DNA. Its potential which retains the modulation of gene expression while wound healing had attracted numerous researchers for efficient DFU wound dressing development. Transfection capacity was already been tested in vitro where PLGA polymers 82 were synthesized to obtain high plasmid loading efficacy and then it was loaded antiangiogenic plasmid DNA (pFlt23k). 83 The PLGA nanoparticles were produced with a help of supercritical fluid extraction method of emulsions based on CO2. The result of the study dictate that the VEGF secretion by epithelial cells was notably decreased, dictating potential value in treatment of DFU.\nDifferent materials can be considered for the nonviral\nDNA carriers for gene therapy like polysaccharides and other cationic polymers. Chitosan is a potential material for long term release of the incorporated drug. 84 Masotti and Ortaggi demonstrated a nanofabrication technique to obtain DNAcontaining chitosan nanospheres (3.8 ± 4 nm). 85 Likewise, Chellat et al. explored the utilization of chitosan to test DNA-loaded nanoparticles. 86 The secretion of MMP-9 in cell supernatants was found to increase appreciably following 24 and 48 hours compared to non treated cells. MMP-2 secretion was found to be greater following 48 hours. Hence, all these results suggest that utilization nanoparticles in gene therapy may accelerate the DFU wound healing.\nPage 5 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "REVIEW RSC Advances",
      "text" : "6 | RSC Advances., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins"
    }, {
      "heading" : "3.4. Nanodelivery routes using stem cells in DFU",
      "text" : "In the last ten years, there were mindboggling\nadvancements in the field nanotechnology for stem cells isolation, maintenance, and regulation. The regulation of stem cells involves the nanoparticles and nano 3D architectures utilization to control stem cells proliferation, differentiation, and maturation. 87 In case of skin regeneration, VEGF high-expressing, transiently modified stem cells have been developed to promote angiogenesis. 88, 89 To circumvent the problem of lack of expression of angiogenic factors and low cell viability after transplantation, nanotechnology has paved a novel solution through nonviral, nanoparticles to deliver hVEGF gene to human mesenchymal stem cells (hMSCs) and human embryonic stem cell-derived cells (hESdCs). This is shown in Fig. 2.\nThe nanotechnology modified stem cells shown improved\nhVEGF production, cell viability, and engraftment into target tissues. The implantation of scaffolds seeded with VEGF-expressing stem cells (hMSCs and hESdCs) was found to form 2 to 4 fold higher\nvessel densities in just 2 weeks following implantation, in comparison to the control cells or cells transfected with VEGF by using Lipofectamine 2000, which is a leading commercial reagent. Four weeks after intramuscular injection into mouse ischemic hindlimbs, genetically modified hMSCs significantly improved angiogenesis and limb salvage, apart from reducing muscle degeneration and tissue fibrosis. 88 These results dictate that stem cells combined with nanotechnology may play a pivotal role in the treatment and management of DFU."
    }, {
      "heading" : "3.5 Nanoparticles for treatment of DFU",
      "text" : "Oxidative stress plays a vital role in etiology of most of\ndiabetic complications. 90, 91 Among all, DFU healing has been the main challenge since it is an intricate process. 92\nHere, the impairment in the healing occurs due to late cellular infiltration and granulation tissue formation, decreased angiogenesis, reduced collagen, and its organization. 93, 94 During the inflammatory phase of wound-healing neutrophils and macrophages invade the wound. The neutrophils will arrive and are\nFig.2 Improved ischemic limb salvage by using biodegradable polymeric nanoparticles. (A) Treated ischemic limbs and controls (B) TTC staining results of muscles (C) Status of ischemic limbs which was studied 4 weeks following surgery. It was classified into three levels; limb salvage, foot necrosis, or limb loss. (D) H&E staining showed massive muscle degeneration in the ischemic regions of control limbs (PBS-injection group), and such muscle degeneration was markedly reduced in group receiving biodegradable polymeric nanoparticles with VEGF (E) Masson’s trichrome staining exhibited notable fibrosis in the control groups. 85\nPage 6 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 7\nPlease do not adjust margins\nPlease do not adjust margins\nabundant at the wound site within one to three hours after wounding. Later, lymphocytes as well as monocytes also will arrive at the wound tissue and later differentiate into activated macrophages. 95 These neutrophils and macrophages will produce\nlarge amounts of superoxide radical anions in which this phenomenon is commonly described as the ‘‘respiratory burst’’. In addition, other cells like fibroblasts can be triggered by proinflammatory cytokines to produce ROS. 96 The production of these reactive molecules is a component of the innate immune system to quickly clean the wound from invading bacteria. 97 Apart from the useful role of microbial killing by ROS, it can also have a series of negative effects. For instance, at lower levels, hydrogen peroxide and other ROS restrict the migration and proliferation of different important cells like keratinocytes. 98 When the ROS is at higher level it can lead to severe tissue damage. 99 Recently, nanoparticles have been discovered to act as free radical scavenger. 100\nCerium oxide (CeO2) nanoparticle is one of the most\nattractive options to be utilized for DFU healing due to its active potential to serve as a free radical scavenger. 101 This metal oxide is monodisperse particle which possess a single crystal and few twin boundaries with expanded lattice parameter. 102, 103 Cerium atom has both +4 and +3 oxidation states. This depicts its dual oxidation state means that these nanoparticles have oxygen vacancies. 104 Generally, when the loss of oxygen occurs, it will lead to the reduction of Ce 4+ to Ce 3+ followed by creation of an oxygen vacancy. This improves the potential of CeO2 nanoparticle to aid in wound healing process followed by scavenging properties.\nYttrium oxide (Y2O3) is also can be considered for the DFU\ntreatment owing to its highest free energy for oxide formation from elemental yttrium compared to other metal oxides. 105 It is characterized by minor alteration from stoichiometry in room temperature and pressure. 106 These types of nanoparticles are commonly non toxic to neutrophiles as well as macrophages. The potential of cerium and yttrium oxide nanoparticles to rescue cells from oxidative stress-induced cell death generally depends on the structure of the nanoparticle. Hence, these nanoparticles may be exploited for the treatment of DFU.\nA thorough literature survey depicts three possible\nmechanisms for the CeO2 and Y2O3 nanoparticles to protect against oxidative stress damage for DFU treatment. (a) They may play a role as direct antioxidants, blocking ROS production, whilst inhibiting programmed cell death pathway (b) They may result in a low level of ROS production, which quickly triggers a ROS defense system before the glutamate-induced cell death program is complete and (c) The triggering of ROS defense system could be caused by the exposure of cells to particulate material known to result in low levels of ROS. 107-109\nSimilarly, nanoparticles made of other metal oxides can\nalso be contemplated for their potential of scavenging to be used for the treatment of DFU. This includes nanoparticles of aluminumoxide (Al2O3), which is commonly called as alumina and silver nitrate. The silver nitrate has been widely used in various clinical studies as an antimicrobial agent for treating chronic wounds. 110 In addition, it is also effective against a spectrum of bacteria, virus and fungi. 110-112 Novel Ag + loaded zirconium phosphate nanoparticles were found to play a significant role in treatment of diabetic wounds. 113 Likewise, gold nanoparticles (AuNPs), are widely explored in recent times for medical applications. 114 The potential of AuNPs to inhibit the lipid from peroxidation and prevent the ROS generation has been found to restore the imbalances in the antioxidants. 115 Barath et al., demonstrated anti-oxidative and antihyperglycemic potential of AuNPs. 116 Hence, these nanoparticles can be utilized for the effective treatment of DFU.\nSilver has been used for the treatment of ulcers since 5th\nCentury B.C. Its antimicrobial activity was first reported in 19th century. However, following discovery of antibiotics in 1940s the utilization of silver salts reduced. Later on, its widely for medical applications, particularly for burn treatment. 117\nThe silver possesses antibacterial effect and low systemic\ntoxicity. 118, 119 It also provides an antibacterial effect that could tremendously decrease the possibility of developing resistance. Nanotechnology introduced novel methods for synthesizing pure biostable silver nanoparticles. 120 In addition, it can be used along with common antibiotic therapy. 120 Extensive in-vivo study depicts\nPage 7 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "REVIEW RSC Advances",
      "text" : "8 | RSC Advances., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\nthat there are multiple ways through which the silver exhibits its antibiotic activity. 121 In addition, it accelerates wound healing rate by promoting proliferation and migration of keratinocytes. 122 The result of the study is shown in Fig. 3. Thus, the silver nanoparticles can be used as a putative candidate for the treatment of DFU.\nIn spite of advanced development of the therapeutic\napplication of silver nanoparticles, it may pose some side effects which must be addressed. Researchers have been analyzing the biosafety aspect of silver nanoparticles for DFU treatment. They have reported that silver nanoparticles have an acceptable biocompatibility, yet occasionally develop argyria. 123 Nanomaterials toxicity is need to be further explored as it is significant to consider the potential health and safety issues. The determinants of particle toxicity are found to have large surface area and chemical reactivity\nwhen they are in small size. It also has the ability to penetrate tissues and cells. 124 Hence, nanoparticles are likely to be more dangerous compared to the same chemicals in larger form, and free particles are more toxic than fixed ones. 125 In addition, the nanoparticles can reach blood circulation and be distributed to\nvarious parts of our body and may result in toxicity. 126 These cases have been researched in vitro and in vivo animal models. However, extensive studies have to be performed in human provided that promising results are obtained in animal trials. Thus, the use of nanoparticles in humans demand detailed studies and more caution.\nFig.3 Silver nanoparticles (AgNp) induced differentiation of fibroblasts into myofibroblasts: A) 3T3 fibroblast cell line with silver sulfadiazine (SSD) and AgNp, and the level of collagen I measured B) Myofibroblasts stained using alpha smooth-muscle actins (α-SMA) after culturing 3T3 fibroblasts with AgNPs or SSD for 48 h C) α -SMA staining of wounds at day 7 in animals treated with either AgNPs or SSD, and comparison against normal skin. 110\nPage 8 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 9\nPlease do not adjust margins\nPlease do not adjust margins"
    }, {
      "heading" : "4. Electrospinning for treatment of DFU",
      "text" : "Traditional wound dressing generally functions as a\ntransitory barrier for hemostasis and prevent infection. 127 Recently, artificial skin grafts have been developed for skin replacement. Yet, the developed products are high in cost, demand extensive care and does not restore complete skin functionality. 128 Hydrogel is a fascinating choice for the treatment of wounds which possess the adavantage of maintaining moisture at the wound site. 129 Nevertheless, most hydrogels are non-degradable and intricate to be used for huge wounds. 130 Till now, conventional medical modalities were unsuccessful to attain satisfactory results in restoring the functionality and the cosmetic appearance of natural skin. 131 The combination of electrospinning and growth factors are gaining popularity nowadays as a potential treatment method to accelerate active wound healing. 132, 133 The platelet-derived growth factor- BB (PDGF-BB) is the only growth factor available in the market which has successfully completed clinical trials. 134 The main constrain with the growth factors is the growth factors are easily degraded by proteinases 135 or eliminated by exudate prior it reaches the wound bed. 136 Recently, efforts have been attempted to deliver growth factors through electrospun nanofibers for healing of DFUs. 137-139 In comparison to conventional wound dressings, the nanofibers fabricated using electrospinning confer an extra cellular matrix (ECM)-like scaffold for supporting skin tissue regeneration. 139, 140 Conversely, without understanding the fundamendals of biological process and fine tuned administration techniques for releasing the biomolecules at critical phases of healing, optimum diabetic wound healing cannot be achieved. 141, 142\nDifferent techniques are utilized for the fabrication of\nelectrospun meshes with capacity to aid diabetic foot healing process whilst eliminating foot ulcer infection. Spectrum of synthetic as well as natural polymers can be integrated for developing materials that can support and supplement the healthy tissue deposition. There are many techniques have been investigated by researchers for loading the nanofibers with growth factors, vitamins, and other biomolecules for improving the DFU healing processes; as shown in Fig. 4. Moreover, momentous focus is given nowadays for encapsulation of drugs, silver nanoparticles, plant-derived compounds like essential oils and honey that possess antimicrobial properties. Ultimately, real-time detection of the\nwound bed environment using pH or temperature, as indicators of the status of the wound also has been explored. 143\nSimilarly, Bertoncel et al., combined novel nanomaterials\nwith PDGF by electrospinning for treating DFU. 144, 145 Platelet-rich plasma (PRP) was used in this study as it is a natural source of growth factor. Later, the hydrophilic nanofibers encapsulated with PRP were fabricated from chitosan and PEO by electrospinning technique. Finally, effects of nanofibers embedded with PRP on cell proliferation, survival, morphology and mobility were studied. In vitro results of the study delineate that PRP triggers keratinocyte and fibroblast cell growth. Optimum concentration of growth medium was found to be 2% (v/v) for both types of skin cells, whilst greater concentrations resulted in modification in cell morphology, with decreased cell mobility and proliferation. The morphology of the electropun sheet observed to be stable even at aqueous environment for 72 hours. Suprisingly, the electrospinning technique was found not to induce any adverse effects on the biological activity of PRP. The nanofiber sheet was also observed to limit the cell mobility, altered cell morphology and trigerred cell proliferation. Even though only a little amount of blood-derived growth factor was used in cell culture through PRP-loaded electrospun sheet, such nanofibrillar support drastically triggered cell proliferation, dictating synergistic effect of nanotopographical morphology and incorporated growth factors. Hence there is a high potential for nanomaterials to deliver PRP to accelerate the diabetic wound healing process.\nBiodegradable polymers were electrospun with EGF\nand/or immobilized on the electrospun sheets for treating DFUs. 146, 147 Amine-terminated block copolymers consisting of PCL and PEG were electrospun to form a nanofibrous sheet with good biocompatibility properties. It was later added with functional amine groups on the surface via PEG linkers. The EGF was chemically conjugated on the surface of with the electrospun sheet. Conjugated quantity of EGF on the electrospun nanofibrous sheet was quantified with XPS. In vitro cell culture study was performed using human primary keratinocytes on EGF-conjugated nanofibrous sheet to investigate the impact of EGF nanofibers on the differentiation of keratinocytes. Later, healing ability of the EGFconjugated nanofibrous sheet was investigated in diabetic induced rats with dorsal wounds. It was found that the expression of\nPage 9 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "REVIEW RSC Advances",
      "text" : "10 | RSC Advances., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\nkeratinocyte-specific genes notably improved by using the EGFconjugated nanofibers. It also demonstrated exceptional in vivo wound healing attributes in comparison to control or EGF solutions. Moreover, immunohistochemical-staining study result dictate that the EGF-receptor (EGFR) was expressed the most in the EGFconjugated nanofibers. Thus, the electrospun EGF-conjugated nanofiber increases the proliferation and phenotypic expression of keratinocytes is a plausible candidate for the DFUs wound treatment.\nDFU is often regarded as intricate to heal because of reduced level of cellular and molecular signals necessary for instigating normal wound repair. 148 Emulsion electrospinning was implemented in a recent study to imbed bFGF into ultrafine fibers forming a core-sheath structure to induce the wound healing process. 138, 148 An initial burst release was found to be as low as 14.0 ± 2.2% was attained, followed by gradual release up to 4 weeks. In vitro studies on mouse embryo fibroblasts showed bFGF-loaded core-sheath nanofibers improved cell adhesion, proliferation, and\nFig.4 Loading of nanofibers with different natural and synthetic components to accelerate the diabetic foot ulcer healing process\nPage 10 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 11\nPlease do not adjust margins\nPlease do not adjust margins\nsecretion of ECM. The skin regeneration ability of the electrospun nanofiber was tested in vivo by creating skin wounds in the dorsal area of diabetic rats followed by the placing the wound healing bFGF-loaded core-sheath nanofibers.\nIn comparison to the fibrous mats infiltrated with free\nbFGF, bFGF-loaded scaffolds showed appreciably increased rate of wound healing with complete re-epithelialization and regeneration of skin appendages. Greater density and mature capillary vessels were formed at the second week following treatment with bFGFloaded fibers, and fiber fragment was absent in the histological sections at the fourth week following operation. The gradual release of bFGF from nanofibrous mats improved collagen deposition and ECM remodeling. Furthermore, the arrangement and component of collagen fibers were found to be similar to normal tissues. Hence, there is a notable potential of bFGF-loaded electrospun nanofibrous mats exist to quickly reinstate the structural and functional properties of affected tissues in patients with DFUs.\nLai et al., studied the collagen (Col) and hyaluronic acid\n(HA) inter-stacking nanofibrous skin equivalent substitute with the programmable release of multiple angiogenic growth factors like vascular endothelial growth factor (VEGF), PDGF, bFGF and EGF. These growth factors were either directly embedded in the nanofibers or encapsulated in the gelatin nanoparticles (GNs) via electrospinning technology. 149, 150 EGF and bFGF delivery at earlier stages was expected to speed up the epithelialization and vasculature sprouting, whilst the release of PDGF and VEGF in the later stage was expected to induce the blood vessels maturation. The mechanical characterization studies suggest that the Col–HA– GN nanofibrous membrane have mechanical properties almost identical to human native skin. The design of a particle-in-fiber structure was found to permit growth factors release up to 1 month. Endothelial cells were cultured on biodegradable Col–HA membrane with four kinds of growth factors (Col–HA w/4GF), it was found that their growth rate increased and formed a better network with a thread-like tubular structure. In vivo studies performed on streptozotocin induced diabetic rats showed an improved wound closure rate, along with elevated collagen deposition and enhanced maturation of blood vessels. Thus, from the obtained results, it is evident that the electrospun Col–HA–GN\ncomposite nanofibrous skin substitute with a stage-wise release pattern of multiple angiogenic factors could be a promising bioengineered construct for chronic DFU treatment."
    }, {
      "heading" : "4.1 Successful cell proliferation and wound",
      "text" : "healing of coaxial electrospinning nanofibers in\nthe treatment of DFU\nThe successful application of the coaxial electrospun\nnanofiber wound dressing is shown in the Fig. 5. 151-153 Here, basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) binary release was achieved from a bFGF/EGF nanofiber patch (Fig. 5a) using coaxial electrospinning method. The core encapsulated with bFGF was found to be released with an initial burst release profile and almost 30% of the encapsulated bFGF and was released within first 12 hours. Yet, the EGF was found to be released by less than 2% within 7 days. This may be attributed due to the surface immobilization of EGF. There are two methods to immobilize the growth factor with the nanofibers which are physical encapsulation and chemical conjugation method. Even though the surface immobilized EGF was released by the degradation of the polycaprolactone-polyethylene glycol, a simple diffusion process was used to deliver the bFGF through the shell of the nanofibers. Based on literature, the thickness of the shell portion of the coaxial electrospun meshes ranges from 100 to 300nm. 154-156 Due to this thin layer, a faster diffusion rate of bFGF was achieved. The high surface-to-volume ratio is one of the major advantages of the nanofibrous matrix since many biological cues can be immobilized on the huge surface area. This results in the efficiency of encapsulated bFGF and surface immobilized EGF on the surrounding cells and tissues maximized. Moreover, dual release of bFGF and EGF is very important as the epidermal cells require different growth factors to accelerate the wound healing process. Hence, optimized release of these two growth factors confers accurate control of the differentiation and proliferation of various cells at the time of re-epithelization.\nIn order to examine the combined effect of bFGF and EGF\non cell proliferation of epidermal cells, human dermal fibroblasts (HDF) and human primary keratinocytes (HPK) were cultivated separately on the bFGF/EGF NF, the bFGF NF, the EGF surface immobilized nanofiber (EGF NF), and the nanofiber (NF), and degree\nPage 11 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "REVIEW RSC Advances",
      "text" : "Please do not adjust margins\nof cell proliferation was compared. 151 The human dermal fibroblasts (HDF) and human primary keratinocytes (HPK) proliferation is shown in Fig. 5b and Fig. 5c, respectively. On the 7 th day, the bFGF/EGF NF exhibited highest proliferation of HDF compared to the EGF since the HDF responds to both EGF and bFGF growth factors. However, when the result of the HPK was compared on the 7 th day, it was found that the EGF NF induced better proliferation rate compared to the bFGF/EGF NF. This is because; even though both EGF and bFGF improves the HPK proliferation the EGF seems to be more specialized growth factor to promote the proliferation of keratinocytes. Thus, HPK and HDF demonstrate different preference of growth factors to improve their proliferation.\nIn vivo testing was performed in dorsal area of diabetic\ninduced mice. 151 After four days, it was found that the wound healing rate of mice subjected with nanofiber patch demonstrated\nhigher wound closure rate than the untreated groups but no difference was observed among the different groups of nanofibers with different growth factors. This substantiate that the either growth factors fail to induce proliferation of epidermal cells at the initial stage of wound healing. However, the nanofibers with the dual growth factors greatly outperformed the other nanofibers for improving the proliferation rate of the epidermal cells improving the wound closure rate by day 7. It was observed that bFGF/EGF NF has a 14.5% better wound healing compared to the bFGF NF and a 22.5% improved wound healing rate than the EGF NF. The in vivo wound closure rates of the diabetic ulcers of the nanofibers fabricated using electrospinning is represented in Fig. 5d. Hence, this clearly shows the potential of electrospinning in the treatment of DFUs.\nPage 12 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 13\nPlease do not adjust margins\nPlease do not adjust margins"
    }, {
      "heading" : "4.2 Nanoparticle-in-fiber system for fast and slow",
      "text" : "biphasic release through electrospinning for the\ntreatment of DFUs\nUtilization of gradually releasing growth factors as\n“cocktail” treatment is an effective approach for curing intricate DFUs. Layer by layer, core-shell electrospinning and etc were explored yet the diffusion between layers remains as a crucial issue to be addressed. 157 The nanoparticle-in-fiber system is a potential strategy to achieve fast and slow biphasic release of two varying growth factors. 158 Vascular endothelial growth factor (VEGF) and platelet-derived growth factor-BB (PDGF-BB) from nanoparticles embedded in the nanofibers release profile is shown in Fig. 6a. An initial burst release of 63% VEGF was observed from nanofibers within one hour. Moreover, the VEGF loaded in the nanofiber of chitosan(CS)/poly(ethylene oxide)(PEO) scaffold achieved 100% release by one day. However, PDGF loaded in the poly-lactic-coglycolic acid (PLGA) nanoparticles demonstrated only initial burst release of just 28% within 2 hours. Moreover, the PDGF-BB release was observed to be in a sustained and controlled profile even at day 7. Hence, a distinct difference can be observed between the release of growth factor which was loaded in the nanofiber and growth factor loaded in a nanoparticle within nanofibers. In wound healing process, VEGF can accelerate the angiogenesis at wound site in the early stage of wound so a rapid delivery of VEGF is required. In contrast, the PDGF-BB encapsulated in the PLGA nanoparticle enables a slower delivery at wound site to induce fibroblast growth in a sustained manner. This fascinating approach of combining nanofibers, growth factors and nanoparticles by electrospinning enables us to control different growth factors release to achieve better wound healing of DFUs.\nHDF was placed on the electrospun nanofibers and MTS assays were performed to determine efficiency of the nanoparticle-in-fiber system to accelerate growth of the HDF. 158 Cell proliferation increased significantly for all the samples compared to the control. It was observed that the 2:1 CS/PEO-NPs sample with PDGF-BB loaded nanoparticles demonstrated quicker cell growth compared to control and scaffolds without growth factors as shown in Fig. 6b. Even in comparison to PDGF-BB, this sample was found to improve cell growth specifically on day 5 and 7 due to the high surface area\nconferred. These results dictate that nanofibrous meshes are cytocompatible and capable of conferring sustained releases profile.\nThe chitosan possess good antibacterial activity. 158 As\nshown in Fig. 6c and 6d, the incorporation of chitosan in the system have resulted in improved antibacterial activity by 10 hours of culture. Similar trend was observed for both gram positive and gram negative bacteria which are E. coli and S. aureus. The Fig. 6e shows the in vivo wound healing efficacy of the nanoparticle-infiber system. 158 It was found wound area for 2:1 CS/PEO-NPs samples with growth factors was significantly smaller against other samples at week 1 and 2, whilst 2:1 CS/PEO without growth factors was found to be almost same as open wound control. Observation of the wound after implantation 1, 2 and 4 weeks of implantation is given in Fig. 7a. 158 Scab was seen on Hydrofera Blue samples only, while nanofibers fabricated by electrospinning obtained almost complete remodeling and hair coverage. Traditionally, when the growth factor activity is increased, it could lead to scar formation. 159, 160\nThe MT and H&E staining performed for ascertaining the\nefficacy of nanoparticle-in-fiber system for DFU healing.\n158\nFig. 7b shows H&E staining of the wound sites at 1 and 2 weeks of treatment whilst Fig. 7c shows that longer epithelial tongues formed on 2:1 CS/PEO-NPs samples, elucidating that GF releasing meshes facilitated the epithelium regeneration in the short term. At the 1 week, more newly formed capillaries for 2:1 CS/ PEO-NPs within the wound site observed compared to open wound, and scaffold without GFs (Fig. 7d). Following 2 weeks of treatment, complete coverage of new epithelium was observed for all samples except the Hydrofera Blue. Fast creeping of epithelium is a supporting factor for faster skin healing post-wounding. 161 Finally, the epithelium of the wound closes completely and the granulation tissue thickness for 2:1 CS/PEO-NPs at week 2 was reduced to great extent compared with the control substantiating that it changed from inflammation phase to proliferation phase (Fig. 7e).\nThe Fig. 7f shows the MT staining results which is used to\nquantify the amount of collagen deposited at the wound site. 158 The 2:1 CS/PEO demonstrated significantly higher collagen deposited compared to Hydrofera Blue at 2 weeks of treatment (Fig. 7g). High number of myofibroblasts, more mature collagen fibers, and less\nPage 13 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "REVIEW RSC Advances",
      "text" : "14 | RSC Advances., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\nnumber of inflammatory cells were observed for the 2:1 CS/PEONPs (in corroboration with H&E results). Greater collagen content at the wound site may aid in the reconstruction of the ECM and support skin growth. 162\nYet, in Fig. 7h, it can be seen that the collagen content\nwas the least for the growth factor releasing nanofibers and this is may be resulted due to the mature collagen formation and more\nhair follicles have regenerated. 158 It can be concluded that the nanofiber/nanoparticles patch fabricated using electrospinning confer not only a synergistic delivery of growth factors, but also play a vital role of ECM mimicry and anti-infection fibrous structure\nto accelerate the DFU healing process. Table 2 represents the electrospinning in treatment of DFU and its key findings.\nFig.6 (a) Growth factor release kinetics from nanofibers and nanoparticles within fibers as determined by ELISA. VEGF was released from 1:1 CS/PEO-NPs nanofibers in PBS at 37 °C. PDGF-BB was release from PLGA nanoparticles encapsulated in 1:1 CS/PEO-NPs nanofibers under the same conditions. (b) Cell proliferation on nanofiber scaffolds: 1:1 CS/PEO, 2:1 CS/PEO without growth factors nanoparticles, 2:1 CS/PEO with PLGA nanoparticles loaded with PDGF-BB (2:1 CS/PEO-NPs). Tissue culture plate and free PDGF-BB were served as negative and positive controls, respectively. Nanofiber meshes and controls were seeded with adult human dermal fibroblast (HDFs) and MTS assay was used to quantify the cell viability. Antibacterial assessment of chitosan/PEO-NP scaffolds compared to (c) negative controls (cell suspension and PEO scaffold) and (d) a positive control (Penstrep solution). 1:1 CS/PEO-NPs and 2:1 CS/PEO-NPs scaffolds showed antibacterial activities against both E. coli and S. aureus compared to negative controls. (e) quantitative measurement of wound size reduction. Reprinted with permission from ref. 141. Copyright 2016, Elsevier.\nPage 14 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 15\nPlease do not adjust margins\nPlease do not adjust margins"
    }, {
      "heading" : "5. Current Challenges and Future Prospects",
      "text" : "Recently, nanotechnology revolutionized the medical\nfield. Advanced nanodelivery methods using nanoparticles and nanofibers fabricated through electrospinning are being explored extensively by researchers. This is represented in Fig. 8. There are various nanodelivery routes like polymeric gene delivery system, nanoparticulate drug delivery systems, free radical scavenging utilizing nanotechnology and etc. These methods are found to be very effective for the treatment of DFUs. This is because, nanomaterials provides different ways to surpass dimensional barrier of the conventional DFU therapies. The nanocariers or nanodelivery has a notable potential to amplify the therapeutic potential of biological and synthetic molecules. But, the impact of nanotechnology treatment on human system has to be assessed meticulously prior to its implementation on clinical trials.\nIt have been suggested that the wound dressing of the\nfuture may incorporate a color map of the wound, pH readout,\ninfection feedback, and an indicator showing if a DFU wound dressing change is necessary. For developing such an intricate wound management system, many fundamental milestones are needed to be achieved. A potential strategy to overcome biofilm formation in the DFU wound bed could be developing a nanofiber mesh using electrospinning that is able to attract bacteria and trap them within its fibrous structure. By integrating such a system with sensors for triggered drug release, a smart dressing would be achieved, that would be capable of reducing the bacterial load in the diabetic wound bed, treat infection only if it occurs, and stimulate growth of healthy tissue.\nThe nanofibers seem to possess potential advantages\ncompared to the nanoparticles. Based upon our knowledge, this advantage lies mostly on the morphology of the fibers in the applications of DFU treatment. As we know skin regeneration require proper scaffolding and this is naturally provided by the extracellular matrix (ECM). This ECM contains several proteins like collagen, fibronectin, laminin etc and these proteins morphology\nFig.7 (a) Representative macroscopic appearance of wound closure at 0, 1, 2, and 4 weeks after treatment of skin wound of control, 2:1 CS/PEO, 2:1 CS/PEO-NPs, and Hydrofera Blue after 0, 1, 2, and 4 weeks; Histological evaluation of wounds treated by CS/PEO-NP meshes. (b) H&E staining for skin wound samples of control (open wound), 2:1 CS/PEO, 2:1 CS/PEO-NPs, Hydrofera Blue after 1 and 2 weeks of treatment; inflammatory cells were indicated by arrows; (c) epithelial length after 1 week of treatment; (d) capillary density at wound site after 1 and 2 weeks of treatment; and (e) granulation tissue thickness after 1 and 2 weeks of treatment. Collagen staining images and quantification of wounds treated by CS/PEO-NP meshes. (f) Masson’s Trichrome staining of each wound samples: control, 2:1 CS/PEO, 2:1 CS/PEO-NPs, and Hydrofera Blue at 2 and 4 weeks of treatment; inflammatory cells were indicated by arrows; collagen quantification of each wound area at 2 (g) and 4 (h) weeks of treatment. Reprinted with permission from ref. 141. Copyright 2016, Elsevier.\nPage 15 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "REVIEW RSC Advances",
      "text" : "16 | RSC Advances., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\nare closer to the nanofiber and hence the bio-mimicking is expected. 163, 164 However, the larger surface area of the nanoparticles make it highly functional and therefore we surmise that combining both renders synergism in the DFU treatments.\nSynergetic functioning of nanofibers with active\nproperties using electrospining can lay a solid foundation in the DFU wound dressing of the future. Biosensors which can be integrated within the dressing must be capable of detecting low levels of bacterial contamination and emit a recognizable output indicative of infection risk. The sensor will trigger a material response that releases a pre-loaded drug with a required release profile as per the conditions of the DFU. The triggered release could be attained by combining switchable surfaces or stimuli-responsive materials into the DFU wound dressing material. 165 At the same time the sensor must confer the doctor/patient with values of different parameters\nindicative of the status of the DFU wound, specifically pH, temperature, moisture, and exudates production."
    }, {
      "heading" : "Acknowledgements",
      "text" : "This work was supported partly by the Ministry of Higher Education Malaysia with the FRGS Grant Vot number: Q.J130000.2545.12H80.\nFig. 8 Nanodelivery routes for diabetic foot ulcer treatment\nPage 16 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K\nRSC Advances\nReview\nThis journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 17\nPlease do not adjust margins\nTable 1: Nanoparticles in treatment of DFU and its key findings\nS.No Technique Base Material Endogenous molecules Key findings Ref\n1 Conjugation Iron oxide\nnanoparticles (γ-Fe2O3 conjugation).\nThrombin Wound response to the treatment of γ-Fe2-O3 was\nremarkable\nWound’s tensile strength was analyzed indicates\nappreciable acceleration of healing process\n48,49\n2 NO-releasing\nnanodelivery\nHydrogel Nitric oxide Sustained release provides an advantage to the\nnanoparticles compared to other vehicles\nEasy storage, application and the provision to change\nthe release rate and concentration\nMinimal risk of toxicity\nPossess good bactericidal activity\n50,54,55\nPage 17 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K\nREVIEW RSC Advances\n18 | RSC Advances ., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\n3 Biodegradable\nnanocarriers\nHyaluronan-based (HYAFF11) porous nanoparticles\nPDGF Release of PDGF periodically as well as in a controlled\nmanner.\nAccelerate chronic wound healing via a stimulation of\nchemotaxis, proliferation and ECM deposition\n63-65\n4 Nanoparticulate\ncarriers\nLipid nanoparticles Opioids, Morphine Opioids trigger cell migration and leads to the closure\nof the experimental wounds\nAccelerate the reepethilialization in a human 3D\nwound healing modal\nKeratinocytes almost covered the wound in just four\ndays\nDecreased cytotoxicity, irritation, extended period of\nthe morphine release\n66-68\n5 Managing the\nenzymatic activity of Matrix metallo proteinases (MMPs)\nMMPs Protease inhibitors, Aspirin-\ntriggered D1 and lipoxin A4\nPolymorphonuclear cell influx displayed good result in\nreducing the wound size\n69-71\n6 Nanoparticulate drug\ndelivery systems\nCarboxymethyl chitosan-based nanoparticles and folic acid tagged chitosan Vancomycin Drug concentration was maintained to be more than the minimal inhibitory limit for 24 hours\nProved its effectiveness against drug-resistant\nstaphylococcal strains\nDrug resistant S. aureus strains the tolerance level\nreduced when nanoconjugated vancomycin was used\n75-79\nPage 18 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K\nRSC Advances REVIEW\nThis journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 19\nPlease do not adjust margins\nPlease do not adjust margins\n7 Drug encapsulation\nwithin nanoparticles\nEmulsion of polyacrylate nanoparticle\nN-methylthiolated β-lactams It possesses different structure-activity patterns\nPutative application is limited due to its poor water\nsolubility property\nIn vitro studies dictate the nanoparticles are nontoxic\nto human skin cells\n80,81\n8 Polymeric gene delivery\nsystem\nPLGA nanoparticles Plasmid DNA Retains the modulation of gene expression while\nwound healing\nTransfection capacity was already been tested in vitro\nVEGF secretion by epithelial cells was notably\ndecreased\n82,83\n9 Polymeric gene delivery\nsystem\nChitosan nanospheres Plasmid DNA The secretion of MMP-9 in cell supernatants was\nfound to increase appreciably following 24 and 48 hours\nMMP-2 secretion was found to be greater following\n48 hours.\n84-86\n10 Nanotechnology\nmodified stem cells\nHuman mesenchymal stem cells (hMSCs) and human embryonic stem cell-derived cells (hESdCs) hVEGF gene Implantation of scaffolds seeded with VEGFexpressing stem cells (hMSCs and hESdCs) was found to form 2 to 4 fold higher vessel densities\ngenetically modified hMSCs significantly improved\nangiogenesis and limb salvage\nReduced muscle degeneration and tissue fibrosis\n87-89\nPage 19 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K\nREVIEW RSC Advances\n20 | RSC Advances ., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\n11 Free radical scavenging\nutilizing nanotechnology\nCerium oxide - Reduction of Ce 4+ to Ce 3+ followed by creation of an\noxygen vacancy\nImproved wound healing\n101-103\n12 Protection against\noxidative stress damage\nCerium oxide and yttrium oxide nanoparticles\n- Block ROS production\nInhibiting programmed cell death pathway\nTriggers ROS defense system\n105-109\n13 Metal oxides for\nscavenging\nAluminumoxide and gold nanoparticles(AuNp)\n- Possess biocompatibility\nHigh surface reactivity\nResistance to oxidation and plasmon resonance\nAuNp inhibit the lipid from peroxidation and prevent\nthe ROS generation\nRestore the imbalances in the antioxidants\n110-116\n14 Biostable nanoparticles\nsynthesis using nanotechnology\nSilver nanoparticles(Ag Np)\n- Antibacterial and antifungal activity\nused along with common antibiotic therapy\nPromotion of proliferation and migration of\nkeratinocytes\nAgNp have an acceptable biocompatibility yet\noccasionally develop argyria\n118-122\nPage 20 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K\nRSC Advances REVIEW\nThis journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 21\nPlease do not adjust margins\nPlease do not adjust margins\nTable 2: Electrospinning in treatment of DFU and its key findings\nS.No Technique Base Material Growth Factor\nUsed"
    }, {
      "heading" : "Form of Electrospun",
      "text" : "Material\nKey findings Ref\n1 Co-axial\nelectrospinning\nAminefunctionalized block copolymers comprised of poly(ecaprolactone) (PCL) and poly(ethyleneglyc ol) (PEG) Basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) Fibers X-ray photoelectron spectroscopy revealed distinctive peaks of nitrogen atoms, which confirm the presence of a surface-immobilized EGF bFGF demonstrated a high initial burst in 24 h, whilst the EGF displayed no negligible release in 7 days Human primary keratinocyte and fibroblast cells\ncultivated on the nanofiber meshes demonstrated the highest cellular proliferation on mesh comprised of the bFGF and the EGF\nWound closure rates of diabetic ulcers were notably\nincreased in 7 days\nKeratin 14, 5, 1 possessed higher expression levels\nagainst the control groups\nBi-phasic release of bFGF and EGF significantly\nsupported tissue recovery with the similar phenotypes as the original keratinized tissues\nResultant nanofibrous mesh improve the\naccumulation of both collagen and a cemented matrix of keratin\n146,147\nPage 21 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K\nREVIEW RSC Advances\n22 | RSC Advances ., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\n2 Electrospinning Chitosan,\npoly(ethylene oxide)(PEO)\nVascular endothelial growth factor (VEGF) and platelet derived growth factor - BB (PDGF-BB) encapsulated poly(lacticcoglycolic acid) nanoparticles\nCombination of fibers and particles\nObtained nanofibrous composites delivered VEGF\nrapidly and PDGF-BB in a relayed manner\nIt was found to support the fibroblast growth\nmeanwhile exhibited anti-bacterial activities\nnanofiber/nanoparticle scaffolds appreciably\naccelerated the wound healing process by inducing angiogenesis, improving re-epithelialization and controlling granulation tissue formation in rats\nQuicker collagen deposition and earlier remodeling\nat the injured site to achieve a faster full regeneration of skin compared to the commercial Hydrofera Blue wound dressing material\n157,158\n3 Electrospinning Chitosan and PEO Platelet-rich\nplasma\nFibers The platelet-rich plasma stimulates keratinocyte and\nfibroblast cell growth in vitro\nOptimum concentration in growth medium was\nfound to be 2% (v/v) for both types of skin cells\nHigher concentrations resulted in modification in cell\nmorphology, with decreased cell mobility and proliferation\nThe morphology of nanofibers observed to be stable\neven in aqueous conditions for 72 h\nElectrospinning does not induce adverse effects on\nthe biological activity of platelet-rich plasma\nNanofibrillar support drastically triggered cell\nproliferation, indicating synergistic effect of nanotopography and incorporated growth factors\n144,145\n4 Electrospinning Amine-\nterminated block\nEGF Fibers Conjugated quantity of EGF on the nanofibers was\nquantified with X-ray photoelectron scattering\n146,147\nPage 22 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K\nRSC Advances REVIEW\nThis journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 23\nPlease do not adjust margins\nPlease do not adjust margins\ncopolymers consisting of PCL and PEG Expression of keratinocyte-specific genes notably\nincreased with the utilization of EGF-conjugated nanofibers\nDemonstrated exceptional in vivo wound healing\nactivities in comparison to control groups\nImmuno histochemical-staining results dictate that\nthe EGF-receptor (EGFR) was highly expressed in the EGF nanofiber group\n5 Emulsion\nelectrospinning\nPoly(ethylene glycol)-poly(DLlactide) (PELA)\nbFGF Fibers Initial burst release was found to be as low as 14.0 ±\n2.2% was attained\nThis is followed by gradual release for around 4 week\nIn vitro studies on mouse embryo fibroblasts showed\nthat bFGF-loaded fibrous mats improved cell adhesion, proliferation, and secretion of extracellular matrix (ECM)\nbFGF-loaded scaffolds showed appreciably\nincreased wound recovery rate with complete reepithelialization and regeneration of skin appendages\nGreater density and mature capillary vessels were\ngenerated during second week\nThere was no fiber fragment observed in the\nhistological sections during the fourth week after operation\nGradual release of bFGF from nanofibrous mats\nimproved collagen deposition and ECM remodeling\n138,148\nPage 23 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K\nREVIEW RSC Advances\n24 | RSC Advances ., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\nArrangement and component of collagen fibers were\nfound to be similar to normal tissues\n6 Electrospinning Collagen (Col)\nand hyaluronic acid (HA)\nVEGF, PDGF, bFGF and EGF either directly embedded or encapsulated in the gelatin nanoparticles (GNs)\nCombination of fibers and nanoparticles\nPhysiochemical characterizations suggest that the\nCol–HA–GN nanofibrous membrane have mechanical properties almost identical to human native skin\nFiber structure was found to permit growth factors\nslow controlled release up to 1 month\nEndothelial cells was not only found to be increased\nin growth rate but also observed to form a better network with a thread-like tubular structure\nIn vivo results show improved wound closure rate,\nalong with elevated collagen deposition and enhanced maturation of vessels\n149,150\nPage 24 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "RSC Advances",
      "text" : "Review\nThis journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 25\nPlease do not adjust margins"
    }, {
      "heading" : "REVIEW RSC Advances",
      "text" : "26 | RSC Advances., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\n45. D. H. Carney, R. Mann, W. R. Redin, S. D. Pernia, D. Berry,\nJ. P. Heggers, P. G. Hayward, M. C. Robson, J. Christie, C. Annable, J. W. Fenton Ii and K. C. Glenn, Journal of Clinical Investigation, 1992, 89, 1469-1477.\n46. U. Amara, D. Rittirsch, M. Flierl, U. Bruckner, A. Klos, F.\nGebhard, J. D. Lambris and M. Huber-Lang, in Advances in Experimental Medicine and Biology, 2008, vol. 632, pp. 71-79.\n47. K. C. Glenn, G. H. Frost, J. S. Bergmann and D. H. Carney,\nPeptide research, 1988, 1, 65-73.\n48. O. Ziv-Polat, M. Topaz, T. Brosh and S. Margel,\nBiomaterials, 2010, 31, 741-747.\n49. S. Das and A. B. Baker, Frontiers in Bioengineering and\nBiotechnology, 2016, 4, 82.\n50. M. R. Schaffer, P. A. Efron, F. J. Thornton, K. Klingel, S. S.\nGross and A. Barbul, Journal of immunology (Baltimore, Md. : 1950), 1997, 158, 2375-2381.\n51. R. Weller, R. J. Price, A. D. Ormerod, N. Benjamin and C.\nLeifert, Journal of Applied Microbiology, 2001, 90, 648- 652.\n52. L. Englande and A. Friedman, Journal of Clinical and\nAesthetic Dermatology, 2010, 3, 45-50.\n53. A. J. Friedman, G. Han, M. S. Navati, M. Chacko, L.\nGunther, A. Alfieri and J. M. Friedman, Nitric Oxide - Biology and Chemistry, 2008, 19, 12-20.\n54. C. Miller, B. McMullin, A. Ghaffari, A. Stenzler, N. Pick, D.\nRoscoe, A. Ghahary, J. Road and Y. Av-Gay, Nitric Oxide - Biology and Chemistry, 2009, 20, 16-23.\n55. L. R. Martinez, G. Han, M. Chacko, M. R. Mihu, M.\nJacobson, P. Gialanella, A. J. Friedman, J. D. Nosanchuk and J. M. Friedman, Journal of Investigative Dermatology, 2009, 129, 2463-2469.\n56. N. Barraud, D. Schleheck, J. Klebensberger, J. S. Webb, D.\nJ. Hassett, S. A. Rice and S. Kjelleberg, Journal of Bacteriology, 2009, 191, 7333-7342.\n57. M. R. Mihu, U. Sandkovsky, G. Han, J. M. Friedman, J. D.\nNosanchuk and L. R. Martinez, Virulence, 2010, 1, 62-67.\n58. A. Y. Peleg, H. Seifert and D. L. Paterson, Clinical\nMicrobiology Reviews, 2008, 21, 538-582.\n59. P. A. Tran, L. Zhang and T. J. Webster, Advanced drug\ndelivery reviews, 2009, 61, 1097-1114.\n60. Z. Deǧim, Journal of Drug Targeting, 2008, 16, 437-448. 61. G. Molineux, Cancer Treatment Reviews, 2002, 28, 13-16. 62. O. I. Corrigan and X. Li, European journal of\npharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2009, 37, 477- 485.\n63. B. Zavan, V. Vindigni, K. Vezzù, G. Zorzato, C. Luni, G.\nAbatangelo, N. Elvassore and R. Cortivo, J Mater Sci: Mater Med, 2009, 20, 235-247.\n64. D. R. Knighton, K. F. Ciresi, V. D. Fiegel, L. L. Austin and E.\nL. Butler, Annals of Surgery, 1986, 204, 322-330.\n65. S. Lepidi, G. Abatangelo, V. Vindigni, G. P. Deriu, B. Zavan,\nC. Tonello and R. Cortivo, FASEB Journal, 2006, 20, 103- 105.\n66. N. B. Wolf, S. Kuchler, M. R. Radowski, T. Blaschke, K. D.\nKramer, G. Weindl, B. Kleuser, R. Haag and M. SchaferKorting, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2009, 73, 34- 42.\n67. P. L. Bigliardi, D. J. Tobin, C. Gaveriaux-Ruff and M.\nBigliardi-Qi, Experimental Dermatology, 2009, 18, 424- 430.\n68. S. Kuchler, N. B. Wolf, S. Heilmann, G. Weindl, J.\nHelfmann, M. M. Yahya, C. Stein and M. Schafer-Korting, J Biotechnol, 2010, 148, 24-30.\n69. C. L. Baum and C. J. Arpey, Dermatologic Surgery, 2005,\n31, 674-686.\n70. L. V. Norling, M. Spite, R. Yang, R. J. Flower, M. Perretti\nand C. N. Serhan, Journal of immunology (Baltimore, Md. : 1950), 2011, 186, 5543-5547.\n71. M. P. Caley, V. L. C. Martins and E. A. O'Toole, Advances in\nwound care, 2015, 4, 225-234.\n72. J. Hurlow and P. G. Bowler, Ostomy Wound Management,\n2009, 55, 38-49.\n73. M. Qadan and W. G. Cheadle, Surgical Clinics of North\nAmerica, 2009, 89, 295-310.\n74. S. M. Moghimi, A. C. Hunter and J. C. Murray,\nPharmacological Reviews, 2001, 53, 283-318.\n75. W. Hachicha, L. Kodjikian and H. Fessi, International\nJournal of Pharmaceutics, 2006, 324, 176-184.\n76. C. Subhankari Prasad, S. Sumanta Kumar, M. Santanu Kar,\nS. Susmita, B. Manjusri, R. Somenath and P. Panchanan, Nanotechnology, 2010, 21, 105103.\n77. S. P. Chakraborty, S. K. Sahu, S. K. Mahapatra, S. Santra,\nM. Bal, S. Roy and P. Pramanik, Nanotechnology, 2010, 21, 105103.\n78. G. J. Russell-Jones, Advanced drug delivery reviews, 1996,\n20, 83-97.\n79. I. Tamai and A. Tsuji, Advanced drug delivery reviews,\n1996, 20, 5-32.\n80. K. Greenhalgh and E. Turos, Nanomedicine:\nNanotechnology, Biology, and Medicine, 2009, 5, 46-54.\n81. E. Turos, J. Y. Shim, Y. Wang, K. Greenhalgh, G. S. K.\nReddy, S. Dickey and D. V. Lim, Bioorganic and Medicinal Chemistry Letters, 2007, 17, 53-56.\n82. I.-S. Kim, S.-K. Lee, Y.-M. Park, Y.-B. Lee, S.-C. Shin, K. C.\nLee and I.-J. Oh, International Journal of Pharmaceutics, 2005, 298, 255-262.\n83. A. S. Mayo, B. K. Ambati and U. B. Kompella, International\nJournal of Pharmaceutics, 2010, 387, 278-285.\n84. A. Masotti, F. Bordi, G. Ortaggi, F. Marino and C. Palocci,\nNanotechnology, 2008, 19.\n85. A. Masotti and G. Ortaggi, Mini-Reviews in Medicinal\nChemistry, 2009, 9, 463-469.\n86. F. Chellat, A. Grandjean-Laquerriere, R. Le Naour, J.\nFernandes, L. H. Yahia, M. Guenounou and D. LaurentMaquin, Biomaterials, 2005, 26, 961-970.\n87. X. Yang, J. D. Shah and H. Wang, Tissue Engineering - Part\nA, 2009, 15, 945-956.\n88. C. S. Yang F, Son SM, Bogatyrev SR, Singh D, Green JJ, Mei\nY, Park S, Bhang SH, Kim BS, Langer R and Anderson DG, Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3317-3322.\n89. E. A. Wahl, T. L. Schenck, H.-G. Machens and E. R.\nBalmayor, Scientific Reports, 2016, 6, 36879.\n90. D. Giugliano, A. Ceriello and G. Paolisso, Diabetes care,\n1996, 19, 257-267.\n91. E. L. Feldman, M. J. Stevens and D. A. Greene, Clinical\nneuroscience (New York, N.Y.), 1997, 4, 365-370.\n92. R. A. Clark, J Am Acad Dermatol, 1985, 13, 701-725. 93. D. L. Coleman, Diabetes, 1982, 31, 1-6.\nPage 26 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2016 RSC Advances., 2016, 00, 1-3 | 27\nPlease do not adjust margins\nPlease do not adjust margins\n94. D. K. Yue, S. McLennan, M. Marsh, Y. W. Mai, J. Spaliviero,\nL. Delbridge, T. Reeve and J. R. Turtle, Diabetes, 1987, 36, 295-299.\n95. A. J. Singer and R. A. Clark, The New England journal of\nmedicine, 1999, 341, 738-746.\n96. B. Meier, H. H. Radeke, S. Selle, M. Younes, H. Sies, K.\nResch and G. G. Habermehl, Biochemical Journal, 1989, 263, 539-545.\n97. R. A. F. Clark, in The Molecular and Cellular Biology of\nWound Repair, eds. R. A. F. Clark and P. M. Henson, Springer US, Boston, MA, 1988, pp. 3-33.\n98. E. A. O'Toole, M. Goel and D. T. Woodley, Dermatologic\nsurgery : official publication for American Society for Dermatologic Surgery [et al.], 1996, 22, 525-529.\n99. P. A. Cerutti and B. F. Trump, Cancer cells (Cold Spring\nHarbor, N.Y. : 1989), 1991, 3, 1-7.\n100. D. B. Warheit, Materials Today, 2004, 7, 32-35. 101. F. Zhang, S.-W. Chan, J. E. Spanier, E. Apak, Q. Jin, R. D.\nRobinson and I. P. Herman, Applied Physics Letters, 2002, 80, 127-129.\n102. V. Perebeinos, S.-W. Chan and F. Zhang, Solid State\nCommunications, 2002, 123, 295-297.\n103. Y. Y. Tsai, J. Oca-Cossio, K. Agering, N. E. Simpson, M. A.\nAtkinson, C. H. Wasserfall, I. Constantinidis and W. Sigmund, Nanomedicine (London, England), 2007, 2, 325- 332.\n104. R. D. Robinson, J. E. Spanier, F. Zhang, S.-W. Chan and I. P.\nHerman, Journal of Applied Physics, 2002, 92, 1936-1941.\n105. T. S. Sudarshan, Materials and Manufacturing Processes,\n1996, 11, 1059-1059.\n106. C. G. Enke, Materials and Corrosion, 1974, 25, 801-802. 107. S. Becker, J. M. Soukup and J. E. Gallagher, Toxicology in\nvitro : an international journal published in association with BIBRA, 2002, 16, 209-218.\n108. G. Zhou, Y. Li, Y. Ma, Z. Liu, L. Cao, D. Wang, S. Liu, W. Xu\nand W. Wang, Journal of Nanoparticle Research, 2016, 18, 135.\n109. A. Hosseini, A. M. Sharifi, M. Abdollahi, R. Najafi, M.\nBaeeri, S. Rayegan, J. Cheshmehnour, S. Hassani, Z. Bayrami and M. Safa, Biological Trace Element Research, 2015, 164, 80-89.\n110. J. B. Wright, K. Lam, D. Hansen and R. E. Burrell, American\nJournal of Infection Control, 1999, 27, 344-350.\n111. W. W. Monafo and C. A. Moyer, Ann N Y Acad Sci, 1968,\n150, 937-945.\n112. H. Q. Yin, R. Langford and R. E. Burrell, The Journal of burn\ncare & rehabilitation, 1999, 20, 195-200.\n113. D. Ruggiero, M. Lecomte, E. Michoud, M. Lagarde and N.\nWiernsperger, Diabetes & metabolism, 1997, 23, 30-42.\n114. R. Guo, Y. Song, G. Wang and R. W. Murray, Journal of the\nAmerican Chemical Society, 2005, 127, 2752-2757.\n115. N. O. Yakimovich, A. A. Ezhevskii, D. V. Guseinov, L. A.\nSmirnova, T. A. Gracheva and K. S. Klychkov, Russian Chemical Bulletin, 2008, 57, 520-523.\n116. S. Barathmanikanth, K. Kalishwaralal, M. Sriram, S. R.\nPandian, H. S. Youn, S. Eom and S. Gurunathan, Journal of nanobiotechnology, 2010, 8, 16.\n117. H. J. Klasen, Burns : journal of the International Society for\nBurn Injuries, 2000, 26, 131-138.\n118. A. Melaiye and W. J. Youngs, Expert Opinion on\nTherapeutic Patents, 2005, 15, 125-130.\n119. J. Fong and F. Wood, International journal of\nnanomedicine, 2006, 1, 441-449.\n120. J. Jain, S. Arora, J. M. Rajwade, P. Omray, S. Khandelwal\nand K. M. Paknikar, Molecular Pharmaceutics, 2009, 6, 1388-1401.\n121. A. D. Widgerow, Burns : journal of the International\nSociety for Burn Injuries, 2010, 36, 965-974.\n122. X. Liu, P. Y. Lee, C. M. Ho, V. C. H. Lui, Y. Chen, C. M. Che,\nP. K. H. Tam and K. K. Y. Wong, ChemMedChem, 2010, 5, 468-475.\n123. J. Ai, E. Biazar, M. Jafarpour, M. Montazeri, A. Majdi, S.\nAminifard, M. Zafari, H. R. Akbari and H. G. Rad, International journal of nanomedicine, 2011, 6, 1117- 1127.\n124. A. Nel, T. Xia, L. Madler and N. Li, Science (New York, N.Y.),\n2006, 311, 622-627.\n125. S. Cavaliere-Jaricot, M. Darbandi, E. Kuçur and T. Nann,\nMicrochimica Acta, 2008, 160, 375-383.\n126. Z. Chen, H. Meng, G. Xing, C. Chen, Y. Zhao, G. Jia, T.\nWang, H. Yuan, C. Ye, F. Zhao, Z. Chai, C. Zhu, X. Fang, B. Ma and L. Wan, Toxicology letters, 2006, 163, 109-120.\n127. J. S. Boateng, K. H. Matthews, H. N. E. Stevens and G. M.\nEccleston, Journal of Pharmaceutical Sciences, 2008, 97, 2892-2923.\n128. S. P. Zhong, Y. Z. Zhang and C. T. Lim, Wiley\nInterdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2010, 2, 510-525.\n129. B. V. Slaughter, S. S. Khurshid, O. Z. Fisher, A.\nKhademhosseini and N. A. Peppas, Advanced Materials, 2009, 21, 3307-3329.\n130. K. Y. Lee and D. J. Mooney, Chemical Reviews, 2001, 101,\n1869-1879.\n131. L. Yildirimer, N. T. K. Thanh and A. M. Seifalian, Trends in\nbiotechnology, 2012, 30, 638-648.\n132. G. F. Pierce and T. A. Mustoe, Annual Review of Medicine,\n1995, 46, 467-481.\n133. K. Obara, M. Ishihara, T. Ishizuka, M. Fujita, Y. Ozeki, T.\nMaehara, Y. Saito, H. Yura, T. Matsui, H. Hattori, M. Kikuchi and A. Kurita, Biomaterials, 2003, 24, 3437-3444.\n134. M. C. Robson, L. G. Phillips, L. E. Robson, A. Thomason and\nG. F. Pierce, The Lancet, 1992, 339, 23-25.\n135. G. S. Schultz, R. G. Sibbald, V. Falanga, E. A. Ayello, C.\nDowsett, K. Harding, M. Romanelli, M. C. Stacey, L. Teot and W. Vanscheidt, Wound Repair and Regeneration, 2003, 11, S1-S28.\n136. R. Jain, A. Agarwal, P. R. Kierski, M. J. Schurr, C. J. Murphy,\nJ. F. McAnulty and N. L. Abbott, Biomaterials, 2013, 34, 340-352.\n137. Y. Yang, T. Xia, W. Zhi, L. Wei, J. Weng, C. Zhang and X. Li,\nBiomaterials, 2011, 32, 4243-4254.\n138. Y. Yang, T. Xia, F. Chen, W. Wei, C. Liu, S. He and X. Li,\nMolecular Pharmaceutics, 2012, 9, 48-58.\n139. J. S. Choi, K. W. Leong and H. S. Yoo, Biomaterials, 2008,\n29, 587-596.\n140. C. Arun Richard, J. Venugopal, S. Sundarrajan and S.\nRamakrishna, Biomedical Materials, 2011, 6, 015001.\n141. M. Ackermann, T. Wolloscheck, A. Wellmann, V. W. Li, W.\nW. Li and M. A. Konerding, European Surgical Research, 2011, 47, 81-89.\n142. M. Ackermann, T. Wolloscheck, A. Wellmann, V. W. Li, W.\nW. Li and M. A. Konerding, International Journal of Molecular Medicine, 2011, 27, 647-653.\nPage 27 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    }, {
      "heading" : "REVIEW RSC Advances",
      "text" : "28 | RSC Advances., 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016\nPlease do not adjust margins\nPlease do not adjust margins\n143. N. Mehmood, A. Hariz, R. Fitridge and N. H. Voelcker,\nJournal of biomedical materials research. Part B, Applied biomaterials, 2014, 102, 885-895.\n144. V. Bertoncelj, J. Pelipenko, J. Kristl, M. Jeras, M. Cukjati\nand P. Kocbek, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2014, 88, 64- 74.\n145. K. M. Lacci and A. Dardik, The Yale Journal of Biology and\nMedicine, 2010, 83, 1-9.\n146. J. S. Choi, K. W. Leong and H. S. Yoo, Biomaterials, 2008,\n29, 587-596.\n147. Y. J. Son, J. Kang, H. S. Kim and H. S. Yoo,\nBiomacromolecules, 2016, 17, 1067-1074.\n148. Y. Yang, T. Xia, W. Zhi, L. Wei, J. Weng, C. Zhang and X. Li,\nBiomaterials, 2011, 32, 4243-4254.\n149. H. J. Lai, C. H. Kuan, H. C. Wu, J. C. Tsai, T. M. Chen, D. J.\nHsieh and T. W. Wang, Acta biomaterialia, 2014, 10, 4156-4166.\n150. K. Lee, E. A. Silva and D. J. Mooney, Journal of the Royal\nSociety Interface, 2011, 8, 153-170.\n151. J. S. Choi, S. H. Choi and H. S. Yoo, Journal of Materials\nChemistry, 2011, 21, 5258-5267.\n152. S. Akita, K. Akino and A. Hirano, Advances in wound care,\n2013, 2, 44-49.\n153. H.-X. Shi, C. Lin, B.-B. Lin, Z.-G. Wang, H.-Y. Zhang, F.-Z.\nWu, Y. Cheng, L.-J. Xiang, D.-J. Guo, X. Luo, G.-Y. Zhang, X.B. Fu, S. Bellusci, X.-K. Li and J. Xiao, PloS one, 2013, 8, e59966.\n154. H. Jiang, Y. Hu, Y. Li, P. Zhao, K. Zhu and W. Chen, Journal\nof Controlled Release, 2005, 108, 237-243.\n155. Y. Zhang, Z.-M. Huang, X. Xu, C. T. Lim and S.\nRamakrishna, Chemistry of Materials, 2004, 16, 3406- 3409.\n156. I. C. Liao, S. Y. Chew and K. W. Leong, Nanomedicine\n(London, England), 2006, 1, 465-471.\n157. K. C. Wood, H. F. Chuang, R. D. Batten, D. M. Lynn and P.\nT. Hammond, Proceedings of the National Academy of Sciences, 2006, 103, 10207-10212.\n158. Z. Xie, C. B. Paras, H. Weng, P. Punnakitikashem, L. C. Su,\nK. Vu, L. Tang, J. Yang and K. T. Nguyen, Acta biomaterialia, 2013, 9, 9351-9359.\n159. P. M. Krein, Y. Huang and B. W. Winston, Expert Opinion\non Therapeutic Patents, 2001, 11, 1065-1079.\n160. T. A. Wilgus, A. M. Ferreira, T. M. Oberyszyn, V. K. Bergdall\nand L. A. DiPietro, Lab Invest, 2008, 88, 579-590.\n161. P. Li, P. Liu, R.-P. Xiong, X.-Y. Chen, Y. Zhao, W.-P. Lu, X.\nLiu, Y.-L. Ning, N. Yang and Y.-G. Zhou, The Journal of Pathology, 2011, 223, 659-671.\n162. J. H. Sung, M.-R. Hwang, J. O. Kim, J. H. Lee, Y. I. Kim, J. H.\nKim, S. W. Chang, S. G. Jin, J. A. Kim, W. S. Lyoo, S. S. Han, S. K. Ku, C. S. Yong and H.-G. Choi, International Journal of Pharmaceutics, 2010, 392, 232-240.\n163. R. Vasita and D. S. Katti, International journal of\nnanomedicine, 2006, 1, 15-30.\n164. P. Karuppuswamy, J. R. Venugopal, B. Navaneethan, A. L.\nLaiva, S. Sridhar and S. Ramakrishna, Applied Surface Science, 2014, 322, 162-168.\n165. R. Ravichandran, S. Sundarrajan, J. R. Venugopal, S.\nMukherjee and S. Ramakrishna, Macromolecular bioscience, 2012, 12, 286-311.\nPage 28 of 29RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K\n1140x928mm (72 x 72 DPI)\nPage 29 of 29 RSC Advances\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 1\nD ec\nem be\nr 20\n16 . D\now nl\noa de\nd on\n0 5/\n12 /2\n01 6\n10 :1\n0: 51\n.\nView Article Online DOI: 10.1039/C6RA24590K"
    } ],
    "references" : [ {
      "title" : "and M",
      "author" : [ "M. Bahrami", "A. Ataie-Jafari", "S. Hosseini", "M.H. Foruzanfar", "M. Rahman" ],
      "venue" : "Pajouhi, International journal of food sciences and nutrition,",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and H",
      "author" : [ "S. Wild", "G. Roglic", "A. Green", "R. Sicre" ],
      "venue" : "King, Diabetes care,",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and E",
      "author" : [ "D.M. Maahs", "N.A. West", "J.M. Lawrenc" ],
      "venue" : "J. Mayer0:  Davis, Endocrinology and metabolism clinics of North  :1  10  America,",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "D",
      "author" : [ "C.C. Cowie", "K.F. Rust", "E.S. Ford", "M.S. Eberhardt" ],
      "venue" : "D.  01  /2  Byrd-Holt, C. Li, D. E. Williams, E. W. Gregg, K. E. 12  Bainbridge, S. H. Saydah and L. S. Geiss, Diabetes care,  5/  0",
      "citeRegEx" : "4",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "D",
      "author" : [ "E.W. Gregg", "B.L. Cadwell", "Y.J. Cheng", "C.C. Cowie" ],
      "venue" : "E. d  de  Williams, L. Geiss, M. M. Engelgau and F. Vinicor, Diabetes oa  care,",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "S",
      "author" : [ "K.H. Yoon", "J.H. Lee", "J.W. Kim", "J.H. Cho", "Y.H. Choi" ],
      "venue" : "H.  ow Ko, P. Zimmet and H. Y. Son, Lancet, 2006, 368, 1681 D  .  16",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 1688
    }, {
      "title" : "The Indian Journal of Medical Research, 2010, r  be 132, 475-477",
      "author" : [ "Y. Wenying" ],
      "venue" : null,
      "citeRegEx" : "7",
      "shortCiteRegEx" : "7",
      "year" : 2010
    }, {
      "title" : "and B",
      "author" : [ "N. Singh", "D.G. Armstron" ],
      "venue" : "A. Lipsky, Jama,",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "G",
      "author" : [ "L.A. Lavery", "K.R. Higgins", "D.R. Lanctot" ],
      "venue" : "P.  0 on Constantinides, R. G. Zamorano, K. A. Athanasiou, D. G. d  Armstrong and C. M. Agrawal, Diabetes care,",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and E",
      "author" : [ "R.E. Pecoraro", "G.E. Reibe" ],
      "venue" : "M. Burgess, Diabetes  Pu care,",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 1990
    }, {
      "title" : "and A",
      "author" : [ "J. Larsson", "C.D. Agardh", "J. Apelqvis" ],
      "venue" : "Stenstrom, Clinical orthopaedics and related research,",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 1998
    }, {
      "title" : "and L",
      "author" : [ "J.A. Mayfield", "G.E. Reiber", "L.J. Sanders", "D. Janiss" ],
      "venue" : "M. Pogach, Diabetes care,",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 1998
    }, {
      "title" : "and B",
      "author" : [ "D.G. Armstron" ],
      "venue" : "A. Lipsky, International wound journal,",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and B",
      "author" : [ "L.A. Lavery", "D.G. Armstrong", "R.P. Wunderlich", "M.J. Mohler", "C.S. Wende" ],
      "venue" : "A. Lipsky, Diabetes care,",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and J",
      "author" : [ "B.A. Lipsky", "A.R. Berendt", "H.G. Deery", "J.M. Embil", "W.S. Joseph", "A.W. Karchmer", "J.L. LeFrock", "D.P. Lew", "J.T. Mader", "C. Norde" ],
      "venue" : "S. Tan, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and R",
      "author" : [ "T. Zgonis", "J.J. Stapleton", "V.A. Girard-Powel" ],
      "venue" : "T. Hagino, AORN journal,",
      "citeRegEx" : "17",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and E",
      "author" : [ "N. Tentolouris", "S. Al-Sabbagh", "M.G. Walker", "A.J. Boulto" ],
      "venue" : "B. Jude, Diabetes care,",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2004
    } ],
    "referenceMentions" : [ ],
    "year" : 2016,
    "abstractText" : "Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the ethical guidelines, outlined in our author and reviewer resource centre, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. Accepted Manuscript",
    "creator" : "Aspose Ltd."
  }
}